Alvin Shih, Retrophin’s (NASDAQ: RTRX) executive vice president and head of R&D, will leave the San Diego-based company at the end of the month. Shih has taken an offer to be the CEO of an unidentified biotech startup.
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
Sponsored · Webinar
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX
